CNR2 and myeloid sarcoma: To determine whether activation of CB2 signaling could prevent the depression-like behavior in MS females, subjects were treated with the CB2 agonist 2.5 mg/kg HU-308 on P30, 32, 34, 36, and 38 following our previous intervention protocol (timeline in Figure 5a; [17]).